Oramed Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $220.55 Mil.
During the past 12 months, Oramed Pharmaceuticals's average Total Assets Growth Rate was 887.90% per year.
During the past 3 years, the average Total Assets Growth Rate was 131.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 36.50% per year.
During the past 10 years, the average Total Assets Growth Rate was 42.10% per year.
During the past 13 years, Oramed Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 700.00%. The lowest was -41.40%. And the median was 35.50%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Oramed Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oramed Pharmaceuticals (NAS:ORMP) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Oramed Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Oramed Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Oramed Pharmaceuticals (Oramed Pharmaceuticals) Business Description
Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ORMP has been successfully added to your 